The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions. Below is a review of novel drug and biological products ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other ...

largely due to product sales of Ohtuvayre. Secondly, the company’s strategic projects like Ensifentrine hold future potential for investors. It is a first-in-class dual inhibitor of PDE3 and ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing the rate of exacerbations over a 24-week period. In ...